Novartis Gene Therapies - Strategic SWOT Analysis Review

October 2021 | 21 pages | ID: A24030414B26EN
GlobalData

Abstracts

Novartis Gene Therapies - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Novartis Gene Therapies, formerly AveXis Inc, is a biotechnology company. It operates as a subsidiary of Novartis AG. The company develops treatments for rare and potentially fatal neurological genetic diseases. The company’s product, Zolgensm is a proprietary gene therapy candidate for pediatric patients for the treatment of spinal muscular atrophy. It is also pursuing gene therapies for Rett syndrome (AVXS-201), and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301). It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. Novartis Gene Therapies is headquartered in Bannockburn, Illinois, the US.

Novartis Gene Therapies Key Recent Developments

Aug 06,2020: Catalent gene therapy facility receives FDA approval as an additional manufacturing site for AveXis’ gene therapy

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Novartis Gene Therapies - Key Facts
Novartis Gene Therapies - Key Employees
Novartis Gene Therapies - Major Products and Services
Novartis Gene Therapies - History
Novartis Gene Therapies - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Novartis Gene Therapies - Business Description
Novartis Gene Therapies - SWOT Analysis
SWOT Analysis - Overview
Novartis Gene Therapies - Strengths
Novartis Gene Therapies - Weaknesses
Novartis Gene Therapies - Opportunities
Novartis Gene Therapies - Threats
Novartis Gene Therapies - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis Gene Therapies, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Aug 06, 2020: Catalent gene therapy facility receives FDA approval as an additional manufacturing site for AveXis’ gene therapy

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Novartis Gene Therapies, Key Facts
Novartis Gene Therapies, Key Employees
Novartis Gene Therapies, Major Products and Services
Novartis Gene Therapies, History
Novartis Gene Therapies, Subsidiaries
Novartis Gene Therapies, Key Competitors
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis Gene Therapies, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021